日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

针对FGFR4的嵌合抗原受体T细胞疗法在横纹肌肉瘤中的临床前开发

Meijie Tian ,Jun S Wei ,Nityashree Shivaprasad ,Steven L Highfill ,Berkley E Gryder ,David Milewski ,G Tom Brown ,Larry Moses ,Hannah Song ,Jerry T Wu ,Peter Azorsa ,Jeetendra Kumar ,Dina Schneider ,Hsien-Chao Chou ,Young K Song ,Abdelrahman Rahmy ,Katherine E Masih ,Yong Yean Kim ,Brian Belyea ,Corinne M Linardic ,Boro Dropulic ,Peter M Sullivan ,Poul H Sorensen ,Dimiter S Dimitrov ,John M Maris ,Crystal L Mackall ,Rimas J Orentas ,Adam T Cheuk ,Javed Khan

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma

针对 GPC2 或 CD276 的优化双顺反子嵌合抗原受体克服了神经母细胞瘤中的异质性表达

Meijie Tian, Adam T Cheuk, Jun S Wei, Abdalla Abdelmaksoud, Hsien-Chao Chou, David Milewski, Michael C Kelly, Young K Song, Christopher M Dower, Nan Li, Haiying Qin, Yong Yean Kim, Jerry T Wu, Xinyu Wen, Mehdi Benzaoui, Katherine E Masih, Xiaolin Wu, Zhongmei Zhang, Sherif Badr, Naomi Taylor, Brad S

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)

使用抑制剂 ponatinib (AP24534) 靶向横纹肌肉瘤中的野生型和突变激活型 FGFR4

Samuel Q Li, Adam T Cheuk, Jack F Shern, Young K Song, Laura Hurd, Hongling Liao, Jun S Wei, Javed Khan